Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan.
AAPS PharmSciTech. 2012 Dec;13(4):1130-7. doi: 10.1208/s12249-012-9826-z. Epub 2012 Sep 1.
We previously developed a unique four-fluid nozzle spray drier that can produce water-soluble microspheres containing water-insoluble drug nanoparticles in one step without any common solvent between the water-insoluble drug and water-soluble carrier. In the present study, we focused on maltosyl-β-cyclodextrin (malt-β-CD) as a new water-soluble carrier and it was investigated whether drug/malt-β-CD microspheres could improve the bioavailability compared with our previously reported drug/mannitol (MAN) microspheres. The physicochemical properties of bare drug microparticles (ONO-2921, a model water-insoluble drug), drug/MAN microspheres, and drug/malt-β-CD microspheres were evaluated. In vitro aerosol performance, in vitro dissolution rate, and the blood concentration profiles after intratracheal administration were compared between these formulations. The mean diameter of both drug/MAN and drug/malt-β-CD microspheres was approximately 3-5 μm and both exhibited high aerosol performance (>20% in stages 2-7), but drug/malt-β-CD microspheres had superior release properties. Drug/malt-β-CD microspheres dissolved in an aqueous phase within 2 min, while drug/MAN microspheres failed to dissolve in 30 min. Inhalation of drug/malt-β-CD microspheres enhanced the area under the curve of the blood concentration curve by 15.9-fold than that of bare drug microparticles and by 6.1-fold than that of drug/MAN microspheres. Absolute bioavailability (pulmonary/intravenous route) of drug/malt-β-CD microspheres was also much higher (42%) than that of drug/MAN microspheres (6.9%). These results indicate that drug/malt-β-CD microspheres prepared by our four-fluid nozzle spray drier can improve drug solubility and pulmonary delivery.
我们之前开发了一种独特的四流体喷嘴喷雾干燥器,它可以一步生产包含水不溶性药物纳米颗粒的水溶性微球,而水不溶性药物和水溶性载体之间没有任何常见溶剂。在本研究中,我们专注于麦芽葡糖苷-β-环糊精(malt-β-CD)作为一种新的水溶性载体,并研究了药物/malt-β-CD 微球是否可以比我们之前报道的药物/甘露醇(MAN)微球提高生物利用度。评估了裸药微球(ONO-2921,一种模型水不溶性药物)、药物/MAN 微球和药物/malt-β-CD 微球的物理化学性质。比较了这些制剂的体外气溶胶性能、体外溶解速率以及气管内给药后的血药浓度曲线。药物/MAN 和药物/malt-β-CD 微球的平均粒径均约为 3-5μm,且均表现出高的气溶胶性能(阶段 2-7 中超过 20%),但药物/malt-β-CD 微球具有更好的释放性能。药物/malt-β-CD 微球在水相中在 2 分钟内溶解,而药物/MAN 微球在 30 分钟内未能溶解。与裸药微球相比,吸入药物/malt-β-CD 微球使血药浓度曲线下面积增加了 15.9 倍,与药物/MAN 微球相比增加了 6.1 倍。药物/malt-β-CD 微球的绝对生物利用度(肺/静脉途径)也远高于药物/MAN 微球(6.9%)。这些结果表明,我们的四流体喷嘴喷雾干燥器制备的药物/malt-β-CD 微球可以提高药物溶解度和肺递药。